According to the definitive agreements inked between the two companies, Acrotech Biopharma LLC, a subsidiary of Aurobindo, will pay an upfront purchase price of $160 million in cash plus up to $140 million on achieving regulatory and sales-based milestones for the seven products.from Business News: Latest News on Business, Stock Markets, Financial News, India Business & World Business News https://ift.tt/2tLQLcg
